文章核心观点 - 5家公司被列入Zacks Rank 1(强烈买入)名单 [1] - 这些公司在过去60天内,其当前年度盈利预测值均有不同程度的上调 [1] 公司总结 Marex Group plc (MRX) - 这家金融服务平台提供商,其当前年度盈利预测值在过去60天内上调了22.3% [1] AngioDynamics, Inc. (ANGO) - 这家医疗技术公司,其当前年度盈利预测值在过去60天内上调了12.8% [1] Opera Limited (OPRA) - 这家互联网技术公司,其当前年度盈利预测值在过去60天内上调了12.8% [1] Atour Lifestyle Holdings Limited (ATAT) - 这家生活方式酒店公司,其当前年度盈利预测值在过去60天内上调了9.9% [1] Pampa Energía (PAM) - 这家综合电力公司,其当前年度盈利预测值在过去60天内上调了10.7% [1] 其他 - 可以在Zacks网站查看今天所有被列为Zacks Rank 1(强烈买入)的股票 [2]

AngioDynamics, Inc.(ANGO) has initiated the RECOVER-AV clinical trial, a prospective, multinational, single-arm study aimed at assessing the efficacy, safety and long-term outcomes of the AlphaVac Multipurpose Mechanical Aspiration F1885 System for treating acute intermediate-risk pulmonary embolism (PE).Following the success of the U.S.-based APEX-AV trial, which demonstrated significant improvements in right ventricular function and clot burden reduction, RECOVER-AV will enroll patients across 20 European ...

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:Arcturus Therapeutics Holdings Inc. (ARCT) : This biotechnology company has seen the Zacks Consensus Estimate for its current year earnings increasing 40.8% over the last 60 days.M/I Homes, Inc. (MHO) : This homebuilder company has seen the Zacks Consensus Estimate for its current year earnings increasing 8.7% over the last 60 days.First Mid Bancshares, Inc. (FMBH) : This financial holding company has seen the Zacks Consensus Estimate f ...

AngioDynamics, Inc. (ANGO) has announced that its Auryon Atherectomy System has received the CE Mark. This innovative system, designed for the treatment of Peripheral Artery Disease (PAD), including Critical Limb Ischemia (CLI) and In-Stent Restenosis (ISR), utilizes state-of-the-art solid-state laser technology. It stands out as the first laser atherectomy system capable of treating lesions of any type, length, or location with minimal vessel wall impact.AngioDynamics is a pioneering medical technology com ...

文章核心观点 - AngioDynamics公司最近被评级机构Zacks上调至"强烈买入"评级,这反映了公司盈利预期的上升趋势,这是影响股价的最强大力量之一 [1][4] - 公司未来盈利能力的变化,如体现在盈利预测修正中,与股价的近期走势有很强的相关性,这是因为机构投资者会根据盈利预测来估算公司股票的合理价值 [5] - AngioDynamics公司盈利预测的上升和评级的提升,意味着公司基本面有所改善,投资者应该通过推高股价来表示对这一积极趋势的认可 [6] 根据目录分类总结 盈利预测修正对股价的影响 - 公司未来盈利能力的变化,如体现在盈利预测修正中,与股价的近期走势有很强的相关性,这是因为机构投资者会根据盈利预测来估算公司股票的合理价值 [5] - 盈利预测的修正是影响股价的最强大力量之一,这是因为机构投资者会根据盈利预测来决定是否买入或卖出股票 [3][5] Zacks评级体系 - Zacks评级体系有很好的外部审计记录,Zacks第1级(强烈买入)股票自1988年以来的平均年收益率为25% [8] - Zacks评级体系将股票划分为5个等级,其中前20%的股票被评为"强烈买入"或"买入",表明其盈利预测修正优于其他股票,是未来表现良好的候选 [11][12] - AngioDynamics公司被Zacks上调至第1级(强烈买入),表明其盈利预测修正优于市场,未来股价有望上涨 [13] AngioDynamics公司情况 - AngioDynamics公司是一家医疗器械制造商,预计2025财年每股收益为-0.41美元,同比下降7.9% [9] - 过去3个月,分析师对AngioDynamics公司的盈利预测已上调29.3% [10]

文章核心观点 - AngioDynamics (ANGO)股价在过去4周内上涨0.3%,但根据华尔街分析师设定的短期价格目标,该股还有大量上涨空间[1] - 分析师给出的平均目标价为13.33美元,较当前价格上涨77%[1] - 分析师对公司未来盈利前景持乐观态度,这可能是该股有望上涨的合理原因[10] 公司概况 - AngioDynamics是一家专注于医疗器械领域的公司,主要从事血管介入治疗产品的研发和销售[1] - 公司目前被评为Zacks Rank 1(强烈买入),这表明其未来表现可能优于大盘[12] 分析师预测 - 分析师给出的3个短期目标价在13-14美元之间,标准差为0.58美元[2] - 最乐观的目标价预计上涨85.9%,最保守的也有72.6%的上涨空间[2] - 分析师预测一致性较高,标准差较小,表明他们对公司前景看法较为一致[8] - 但分析师给出的目标价并不总能准确预测股价走势[3][5][9] 业绩预期 - 分析师普遍预期公司未来业绩将好于此前预测,这可能是推动股价上涨的一个合理因素[4][10][11] - 过去一个月内,公司当年EPS预测值上调31.7%,这表明分析师对公司前景持乐观态度[11]

From a technical perspective, AngioDynamics, Inc. (ANGO) is looking like an interesting pick, as it just reached a key level of support. ANGO's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.Considered an important signifier for a bullish breakout, a golden cross is a technical chart pattern that's formed when a stock's short-term moving average breaks above a longer-term moving average; the most common crossover involves ...

Shares of AngioDynamics (ANGO) have gained 26.5% over the past four weeks to close the last trading session at $7.65, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $13.33 indicates a potential upside of 74.3%.The average comprises three short-term price targets ranging from a low of $13 to a high of $14, with a standard deviation of $0.58. While the lowest estimate indicates a ...

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:Kronos Worldwide, Inc. (KRO) : This titanium dioxide pigment company has seen the Zacks Consensus Estimate for its current year earnings increasing 12.9% over the last 60 days.First United Corporation (FUNC) : This bank holding company for First United Bank & Trust has seen the Zacks Consensus Estimate for its current year earnings increasing 9.1% over the last 60 days.PROG Holdings, Inc. (PRG) : This financial technology holding compan ...

公司概况 - 公司业务涉及医疗器械产品的研发、生产和销售[14] - 公司面临的主要风险包括技术创新、监管审批、市场竞争、原材料供应等[14] 财务风险 - 公司外汇风险主要来自于销售收入中约3.6%来自于欧元、英镑和加元等外币[326] - 公司无长期债务,利率风险较小[327] - 公司客户集中度较低,无单一客户占总销售10%以上[330] 内部控制 - 公司内部控制和财务报告有效性已经过审计机构审核[339,340] - 公司内部控制体系有效,未发现重大缺陷[337] - 公司管理层对内部控制的有效性进行了评估,认为于2024年5月31日有效[335] - 公司外部审计机构对内部控制的有效性也出具了无保留意见[339] - 公司信息披露控制和程序有效,能够确保重要信息的及时披露[332]